Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Frontiers Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial - The Lancet Oncology

Transcriptome subtyping of metastatic Castration Resistance Prostate Cancer (mCRPC) for the precision therapeutics: an in silico analysis

Nivolumab plus ipilimumab shows benefit in advanced prostate cancer subset

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

Nivolumab: targeting PD-1 to bolster antitumor immunity

VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

Frontiers Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

PDF) Long-term complete remission with Ipilimumab in metastatic castrate- resistant prostate cancer: Case report of two patients

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology

Current therapy and drug resistance in metastatic castration-resistant prostate cancer - ScienceDirect

Management of Castration-Resistant Prostate Cancer

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier, Cancer Cell International